

Marc-Oliver Grimm

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8657706/marc-oliver-grimm-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124
papers

7,177
citations

34
h-index

84
g-index

170
ext. papers

9,598
ext. citations

6
avg, IF

5.4
L-index

#	Paper	IF	Citations
124	Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102631	2.2	1
123	Wnt/ECatenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5319	6.3	0
122	Sequenztherapie des metastasierten Nierenzellkarzinoms. <i>Best Practice Onkologie</i> , 2021 , 16, 603	0	
121	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2021 , 81, 266-266	10.2	4
120	The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells. <i>Oncogene</i> , 2021 ,	9.2	2
119	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. <i>Nature Communications</i> , 2021 , 12, 2301	17.4	24
118	Rate, Factors, and Outcome of Delayed Graft Function After Kidney Transplantation of Deceased Donors. <i>Transplantation Proceedings</i> , 2021 , 53, 1454-1461	1.1	1
117	Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. <i>International Journal of Cancer</i> , 2021 , 148, 1685-1694	7.5	0
116	Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2021 , 79, 429-430	10.2	
115	Antithetic hTERT Regulation by Androgens in Prostate Cancer Cells: hTERT Inhibition Is Mediated by the ING1 and ING2 Tumor Suppressors. <i>Cancers</i> , 2021 , 13,	6.6	1
114	How to Deal with Renal Cell Carcinoma >7 cm: Radical Surgery. <i>European Urology Open Science</i> , 2021 , 33, 81-82	0.9	
113	SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells. <i>Cells</i> , 2021 , 10,	7.9	4
112	Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2020 , 31, 1030-1039	10.3	144
111	Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". <i>European Urology</i> , 2020 , 78, 690-698	10.2	23
110	Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies. <i>Translational Oncology</i> , 2020 , 13, 100801	4.9	3
109	A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. <i>Oncology Research and Treatment</i> , 2020 , 43, 333-339	2.8	6
108	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020 , 11, 364	8.4	30

107	Position Paper of the German Society for Interventional Radiology (DeGIR) on Prostatic Artery Embolization. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020 , 192, 835-846	2.3	0
106	New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	20
105	Prostatic Artery Embolization-Anatomic Predictors of Technical Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2020 , 31, 378-387	2.4	7
104	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 105-120	21.7	35
103	High Detection Rate for Non-Muscle-Invasive Bladder Cancer Using an Approved DNA Methylation Signature Test. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 210-221	3.3	4
102	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. <i>Future Oncology</i> , 2020 , 16, 2307-2328	3.6	9
101	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial 2020 , 8,		68
100	Reply to Emre Karabay and İker Ṫbay Letter to the Editor re: Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". <i>Eur Urol</i> in press.	10.2	1
99	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020 , 5, e001079 ⁶		109
98	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1574-1588	21.7	115
97	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	28
96	Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study. <i>Oncology Research and Treatment</i> , 2019 , 42, 57-66	2.8	1
95	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019 , 76, 368-380	10.2	26
94	Aktuelle medikamentöse Therapiekonzepte des metastasierten Prostatakarzinoms. <i>Onkologie</i> , 2019 , 25, 343-351	0.1	
93	Prospective evaluation study on the benefit of the simultaneous detection of seven sexually transmitted pathogens for the clinical management of patients suffering from sexually transmitted diseases. <i>Journal of Laboratory Medicine</i> , 2019 , 43, 13-20	0.9	
92	Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection. <i>World Journal of Urology</i> , 2019 , 37, 2699-2705	4	10
91	Innate immune response of human epidermal keratinocytes and dermal fibroblasts to in vitro incubation of <i>Trichophyton benhamiae</i> DSM 6916. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1177-1188	4.6	10
90	T2 Mapping in Prostate Cancer. <i>Investigative Radiology</i> , 2019 , 54, 146-152	10.1	30

89	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1370-1385	21.7	343
88	Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4524-4524	2.2	8
87	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 564-564	2.2	6
86	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 581-581	2.2	10
85	In Reply. <i>Deutsches A&#x0308;rztblatt International</i> , 2019 , 116, 192-193	2.5	
84	SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). <i>European Journal of Cancer</i> , 2019 , 107, 37-45	7.5	16
83	A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 811-820	4.9	5
82	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 297-310	21.7	122
81	Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups. <i>Clinical Cancer Research</i> , 2018 , 24, 1586-1593	12.9	48
80	Nichtinvasives Harnblasenkarzinom. <i>Onkologe</i> , 2018 , 24, 23-31	0.1	1
79	Collection of real-world data on nivolumab® effectiveness in renal cell carcinoma: rationale for an observational study. <i>Future Oncology</i> , 2018 , 14, 1023-1034	3.6	1
78	Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study. <i>Urologia Internationalis</i> , 2018 , 101, 16-24	1.9	23
77	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1277-1290	59.2	2064
76	Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study. <i>BJU International</i> , 2018 , 121, 101-110	5.6	13
75	Immunonkologie beim Nierenzellkarzinom [Aktueller Stand. <i>Tumor Diagnostik Und Therapie</i> , 2018 , 39, 321-325	0.1	
74	Prostatic Artery Embolization with 250-µm Spherical Polyzene-Coated Hydrogel Microspheres for Lower Urinary Tract Symptoms with Follow-up MR Imaging. <i>Journal of Vascular and Interventional Radiology</i> , 2018 , 29, 1127-1137	2.4	14
73	The Investigation of Hematuria. <i>Deutsches A&#x0308;rztblatt International</i> , 2018 , 115, 801-807	2.5	24
72	Erstlinientherapie des mRCC: ein Update. <i>Onkologe</i> , 2018 , 24, 809-816	0.1	

71	Prostate Artery Embolization: Indication, Technique and Clinical Results. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2018 , 190, 847-855	2.3	20
70	Evaluation of Plasmatic Kisspetin-10 as a Biomarker for Malignancy and Subtype Differentiation in Small Renal Tumours. <i>Urologia Internationalis</i> , 2017 , 98, 177-183	1.9	4
69	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 312-322	21.7	981
68	Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1757-1769	4.9	8
67	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , 2017 , 57, 36-49	14.4	185
66	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e809-e817	3.3	17
65	Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. <i>European Urology</i> , 2017 , 72, 461-469	10.2	51
64	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2266-2277	4.0	121
63	Gesundheitsbezogene Lebensqualität als prognostisches Maß für klinische Ergebnisse beim RCC. <i>Onkologie</i> , 2017 , 23, 234-236	0.1	
62	Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database. <i>International Urology and Nephrology</i> , 2017 , 49, 247-254	2.3	2
61	The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 356-362	3.3	22
60	High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1515-22	4.3	11
59	Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study. <i>Urologia Internationalis</i> , 2016 , 96, 57-64	1.9	6
58	Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 1171-82	4.9	13
57	Assessment of PI-RADS v2 for the Detection of Prostate Cancer. <i>European Journal of Radiology</i> , 2016 , 85, 726-31	4.7	119
56	A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. <i>European Urology</i> , 2016 , 69, 94-102	10.2	137
55	Prevalence and Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction in a Contemporary Series of Renal Transplant Recipients. <i>Nephro-Urology Monthly</i> , 2016 , 8, e35497	0.4	2
54	Gigantic Suprapubic Lymphedema: A Case Study. <i>World Journal of Men's Health</i> , 2016 , 34, 148-52	6.8	1

53	A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study. <i>Journal of Urology</i> , 2015 , 193, 570-8	2.5	90
52	High-grade Carcinoma of the Proximal Ureter With Negative Nephroureteroscopy Detected by a Positive FISH Test: A Rare Case Report. <i>Urology Case Reports</i> , 2015 , 3, 167-9	0.5	
51	Evidence from the PROspective MulticEnTer Radical Cystectomy Series 2011 (PROMETRICS 2011)O study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer?. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1032-42	3.1	26
50	MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases. <i>Annals of Surgical Oncology</i> , 2014 , 21, 1046-54	3.1	53
49	Reply to Jffne Verine, Christophe Leboeuf and Philippe Ratajczak letter to the editor re: Jimsgene Sanjmyatav, Sven Hauke, Mieczyslaw Gajda, et al. Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. <i>Eur Urol</i> 2013 ;64:689-91. <i>European Urology</i> , 2014 , 65, e71-2	10.2	
48	FISH analysis of washing urine from the upper urinary tract for the detection of urothelial cancers. <i>International Urology and Nephrology</i> , 2014 , 46, 1769-74	2.3	16
47	A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells. <i>Molecular Endocrinology</i> , 2014 , 28, 1831-40		25
46	Placental Schistosoma haematobium infection in a German returnee from Malawi. <i>Infection</i> , 2014 , 42, 1061-4	5.8	11
45	Identification of high-risk patients with clear cell renal cell carcinoma based on interphase-FISH. <i>British Journal of Cancer</i> , 2014 , 110, 2537-43	8.7	4
44	Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. <i>Molecular Cancer</i> , 2014 , 13, 214	42.1	41
43	180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study. <i>European Urology</i> , 2014 , 65, 931-42	10.2	149
42	Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. <i>Investigational New Drugs</i> , 2013 , 31, 1001-7	4.3	21
41	Prostatakarzinom. <i>Onkologe</i> , 2013 , 19, 702-704	0.1	1
40	Operative Therapie des lokal begrenzten Prostatakarzinoms. <i>Onkologe</i> , 2013 , 19, 719-727	0.1	1
39	Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. <i>European Urology</i> , 2013 , 64, 689-91	10.2	5
38	Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma (SWITCH-2 study).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS4591-TPS4591	2.2	3
37	T1-High-Risk-Harnblasenkarzinom. <i>Onkologe</i> , 2012 , 18, 971-976	0.1	
36	CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. <i>International Journal of Cancer</i> , 2012 , 131, E693-704	7.5	50

35	Früherkennung in der Urologie. <i>Onkologe</i> , 2012 , 18, 243-247	0.1	
34	Roboterassistierte laparoskopische Operationen in der Urologie. <i>Onkologe</i> , 2012 , 18, 425-428	0.1	
33	Surgery for renal cell cancer extending into the inferior vena cava - evaluation of survival and perioperative complications using a standardized classification system. <i>BJU International</i> , 2011 , 108, 1439-43	5.6	15
32	The contemporary concept of significant versus insignificant prostate cancer. <i>European Urology</i> , 2011 , 60, 291-303	10.2	224
31	Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2011 , 29, 361-6	4	22
30	Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia?. <i>Prostate</i> , 2011 , 71, 1325-31	4.2	17
29	Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma. <i>Cancer Investigation</i> , 2011 , 29, 123-9	2.1	21
28	Advances in renal cell carcinoma treatment. <i>Therapeutic Advances in Urology</i> , 2010 , 2, 11-7	3.2	17
27	Whole-body MRI in follow-up of patients with renal cell carcinoma. <i>Acta Radiologica</i> , 2010 , 51, 581-9	2	20
26	Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010 , 381, 329-38	3.4	3
25	Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009 , 328, 213-22	4.7	60
24	Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). <i>European Urology</i> , 2009 , 55, 1293-9	10.2	89
23	Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. <i>International Journal of Cancer</i> , 2009 , 125, 474-82	7.5	69
22	A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. <i>Cancer</i> , 2009 , 115, 2881-90	6.4	175
21	Words of wisdom. Re: utilization and outcomes of minimally invasive radical prostatectomy. <i>European Urology</i> , 2008 , 54, 1439-40	10.2	2
20	Clinical and functional results after continent cutaneous urinary diversion with the ileal double-T-pouch. <i>Urologia Internationalis</i> , 2008 , 80, 8-12	1.9	4
19	Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. <i>Anticancer Research</i> , 2008 , 28, 2259-63	2.3	17
18	Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. <i>Cancer</i> , 2007 , 109, 2016-24	6.4	43

17	Radikale Zystektomie und Harnableitung beim Harnblasenkarzinom. <i>Onkologe</i> , 2007 , 13, 1089-1095	0.1	1
16	An alternatively spliced KAI1 mRNA is expressed at low levels in human bladder cancers and bladder cancer cell lines and is not associated with invasive behaviour. <i>Oncology Reports</i> , 2007 , 18, 1357-63	3.5	7
15	DNA methylation alterations in urothelial carcinoma. <i>Cancer Biology and Therapy</i> , 2006 , 5, 993-1001	4.6	44
14	Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. <i>Journal of Urology</i> , 2005 , 174, 862-6; discussion 866	2.5	218
13	KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. <i>Oncogene</i> , 2005 , 24, 637-49	9.2	59
12	Anemia under androgen deprivation: influence of flutamide, cyproteroneacetate and orchiectomy on the erythropoietin system. <i>Hormone and Metabolic Research</i> , 2005 , 37, 89-93	3.1	10
11	Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. <i>Clinical Cancer Research</i> , 2004 , 10, 3410-21	12.9	98
10	Penile metastasis secondary to follicular thyroid carcinoma. <i>Scandinavian Journal of Urology and Nephrology</i> , 2004 , 38, 253-5		16
9	Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. <i>Cancer Letters</i> , 2004 , 215, 209-20	9.9	49
8	Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. <i>Urology</i> , 2004 , 63, 392-7	1.6	21
7	Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. <i>European Urology</i> , 2002 , 41, 628-34; discussion 634	10.2	46
6	Relationship between expression of KAI1 metastasis suppressor gene, mRNA levels and p53 in human bladder and prostate cancer cell lines. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2002 , 7, 99-104	2.8	20
5	Primary treatment of ureteral stones by new multiline lithotripter. <i>Journal of Endourology</i> , 1999 , 13, 339-42	2.7	9
4	Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. <i>Urological Research</i> , 1995 , 23, 293-300		43
3	P53 accumulation in precursor lesions and early stages of bladder cancer. <i>World Journal of Urology</i> , 1994 , 12, 79-83	4	45
2	Risikostratifizierung und Therapiealgorithmus des metastasierten Nierenzellkarzinoms. <i>Onkologe</i> , 1	0.1	
1	An integrated multi-omics analysis identifies clinically relevant molecular subtypes of non-muscle-invasive bladder cancer		1